JP2017518260A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518260A5
JP2017518260A5 JP2016558558A JP2016558558A JP2017518260A5 JP 2017518260 A5 JP2017518260 A5 JP 2017518260A5 JP 2016558558 A JP2016558558 A JP 2016558558A JP 2016558558 A JP2016558558 A JP 2016558558A JP 2017518260 A5 JP2017518260 A5 JP 2017518260A5
Authority
JP
Japan
Prior art keywords
sequence
seq
fragment
mab
tkleik
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016558558A
Other languages
English (en)
Japanese (ja)
Other versions
JP6740135B2 (ja
JP2017518260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/026595 external-priority patent/WO2015161311A2/en
Publication of JP2017518260A publication Critical patent/JP2017518260A/ja
Publication of JP2017518260A5 publication Critical patent/JP2017518260A5/ja
Application granted granted Critical
Publication of JP6740135B2 publication Critical patent/JP6740135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016558558A 2014-04-18 2015-04-20 ヒト化抗−ｔｆ−抗原抗体 Active JP6740135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981240P 2014-04-18 2014-04-18
US61/981,240 2014-04-18
PCT/US2015/026595 WO2015161311A2 (en) 2014-04-18 2015-04-20 Humanized anti-tf-antigen antibodies

Publications (3)

Publication Number Publication Date
JP2017518260A JP2017518260A (ja) 2017-07-06
JP2017518260A5 true JP2017518260A5 (cg-RX-API-DMAC7.html) 2018-05-31
JP6740135B2 JP6740135B2 (ja) 2020-08-12

Family

ID=54324717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558558A Active JP6740135B2 (ja) 2014-04-18 2015-04-20 ヒト化抗−ｔｆ−抗原抗体

Country Status (11)

Country Link
US (1) US11130821B2 (cg-RX-API-DMAC7.html)
EP (2) EP3131581B1 (cg-RX-API-DMAC7.html)
JP (1) JP6740135B2 (cg-RX-API-DMAC7.html)
KR (1) KR102413809B1 (cg-RX-API-DMAC7.html)
CN (1) CN106488774B (cg-RX-API-DMAC7.html)
AU (1) AU2015247358B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016024214B8 (cg-RX-API-DMAC7.html)
ES (1) ES2843546T3 (cg-RX-API-DMAC7.html)
MX (2) MX378944B (cg-RX-API-DMAC7.html)
RU (1) RU2699717C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015161311A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851164B2 (en) * 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
SG11202001401TA (en) * 2017-09-22 2020-04-29 Immunogen Inc Separation of triple-light chain antibodies using cation exchange chromatography
CA3094827A1 (en) * 2018-03-28 2019-10-03 Mitsubishi Tanabe Pharma Corporation Drug conjugates of cmet monoclonal binding agents, and uses thereof
WO2019231957A1 (en) * 2018-05-30 2019-12-05 National Health Research Institutes Anti-abeta antibodies and uses thereof
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
BR112021011982A2 (pt) 2018-12-21 2021-09-14 Ose Immunotherapeutics Anticorpo anti-humano-pd-1 humanizado
AU2019409805A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021194942A1 (en) * 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260680A1 (en) * 2004-04-16 2005-11-24 Vanderbilt University Methods of diagnosing and treating autoimmune diseases
EP1789027B1 (en) 2004-07-26 2013-09-04 The Research Foundation Of State University Of New York Therapeutic use of anti-tf-antigen antibody
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US20070286858A1 (en) * 2006-03-21 2007-12-13 Wyeth Methods and Compositions for Antagonism of RAGE
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
NZ599971A (en) * 2009-10-16 2014-12-24 Servier Lab Monoclonal antibodies to progastrin and their uses
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
KR20230143201A (ko) * 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CN102796144A (zh) * 2012-08-22 2012-11-28 山东大学 Tf抗原及其类似物、和其化学酶法合成方法及其应用
US10023651B2 (en) * 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies

Similar Documents

Publication Publication Date Title
JP2017518260A5 (cg-RX-API-DMAC7.html)
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
EA201792221A1 (ru) Антитела против сортилина и способы их применения
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
MY188362A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
MX2018006333A (es) Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos